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1 Introduction
Molecular components of the extracellular matrix (ECM) are critical for matrix stabilization, cellular
differentiation, and tissue morphogenesis. Once thought to function only as the extracellular glue that
primarily binds cells together, proteoglycans in the ECM carry out a diverse array of activities and can
be grouped into five functionally based families: (i) hyalectins (lecticans), which contain lectin-like carbohydrate-recognition domains (CRDs) and bind hyaluronan (HA); (ii) heparan sulfate (HS) proteoglycans that sequester growth factors via their HS chains; (iii) small leucine-rich proteoglycans (SLRPs)
containing leucine-rich domains that interact with collagens and other ECM proteins; (iv) phosphacans
that function primarily as receptor-like protein-tyrosine phosphatases; and (v) part-time proteoglycans
that reside both on the cell surface and in the ECM. More than 40 cDNAs encoding proteoglycan core
proteins have been discovered thus far [1]. For the sake of brevity, this chapter will focus only on the
four lecticans that bind HA (Figure 1): Aggrecan, neurocan, brevican, and versican.
All lecticans have two N-terminal Link domains, one immunoglobulin-like module, a central glycosaminoglycan (GAG)-attachment region, and one or more EGF-like domains in the C-terminus.
The lecticans are post-translationally modified by O-Linked GAG chains on Ser residues of multiple
Ser-Gly dipeptide repeats. Aggrecan, versican, neurocan, and brevican contain 120, 20, 7, and 3 potential sites, respectively. Generally, the CS chains of the lecticans maintain structural integrity of the
tissue ECM by serving as barrier functions to limit the growth and migration of cells. For example,
the CS chains of neurocan and brevican act as barriers to inhibit neurite outgrowth and migration so
that, hypothetically, dendrites are available for longer periods of time in their local environment to
make the correct synaptic junctions [2] and set up guidance cues for migration [3,4]. The barrier functions of the lecticans exist on two levels: (i) as mechanical barriers, the proteoglycans form neuronal
nets to physically constrain neurite outgrowth [5] and (ii) as cell signaling barriers, the proteoglycans
can activate intracellular signaling pathways regulated by the Rho-family GTPases to promote the
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Figure 1. Lectican domain organization. The common domains of the lecticans include two globular domains, G1 and
G3, and a CS/KS-attachment region (red). The G1 region contains two Link modules (blue) that bind to HA. The G3
domain contains at least two EGF-like regions (yellow), a carbohydrate recognition domain (CRD; green), and a short
complement regulatory region (SRC; black). Glycanated aggrecan is the largest of the lecticans, containing up to 120 CS
and KS chains, in addition to an Ig-fold sequence (IGD; brown) and a G2 region (orange). The four splice variants of
versican (V0–V3) contain N- and C-terminal regions that are very homologous with aggrecan and differing CS-attachment regions (except for V3) encoded by different exons, which are preferentially spliced depending on the host celltype. Versican V0 contains the longest core protein of all the lecticans and contains up to 20 CS chains. Neurocan, with
seven CS chains, and brevican, with three CS chains, differ in size and glycanation and do not contain an Ig-domain
(IGD). Metalloproteolyic cleavage sites for ADAMTS-1/4 or MMP-2 (in neurocan only) are represented by the arrows.

disruption of the actin cytoskeleton and growth cone collapse [6]. In addition to the barrier functions,
GAGs in close proximity may also serve to sequester water to maintain tissue hydration.
Neurocan and brevican are primarily neural ECM lecticans, whereas aggrecan is found mainly in
cartilage and versican is in vascular vessel walls. Aggrecan and versican play minor, albeit important
and sometimes transient, functions in central nervous system (CNS) development and ECM composition [7]. Aggrecan, versican, and brevican are proteolytically degraded by ADAMTS-1/4 (a disintegrin
and metalloproteinase with thrombospondin motifs) metalloproteases, whereas neurocan is processed
by matrix metalloproteinases 2 (MMP-2). Metalloprotease cleavage of the lecticans is part of their normal turnover process and an increase in metalloprotease activity in tissues such as the brain may be
a prerequisite for diseases such as Alzheimer’s disease and epilepsy [8]. Numerous reviews have described the biology, chemistry, and physiological impact of these lecticans, their splice variants, and
their cohorts of interacting partners on matrix and cellular composition in tissues [9-19].
2 Aggrecan
Chondrocytes synthesize and secrete the ECM components of cartilage. The most abundant protein is collagen II, which is up to 60% of the dry weight of the cartilage, followed by aggrecan (35% of
dry weight). All other components make up the remaining 5% of the tissue dry weight [20]. The aggrecan core protein is heavily modified in the endoplasmic reticulum (ER)/Golgi by addition of chondroitin sulfate (CS) and keratan sulfate (KS) chains prior to secretion from the cell. These glycosaminoglycan (GAG) modifications greatly increase the molecular mass of the molecule by at least four- to
five-fold over the core protein alone. After aggrecan is secreted from chondrocytes, it interacts with
HA and Link proteins to form organized structures—proteoglycan aggregates. The CS and KS chains
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are highly sulfated, giving the entire aggrecan molecule a high polyanionic charge, which attracts and
binds large amounts of water and cations. Seventy percent of the wet weight of cartilage is due to water
sequestered by the high-density negative charge associated with the sulfate and carboxylate groups on
the GAGs, giving the tissue a gel-like quality [21]. The viscoelastic behavior of the GAGs in aggrecanHA aggregates is directly responsible for the unique physical properties of articular cartilage, which includes compressive resilience during joint loading and load distribution over the surface of the tissue.
The aggrecan core protein consists of three disulfide-bonded globular domains, G1, G2, and G3,
and a GAG-attachment region, primarily containing CS (Figure 1). The N-terminus of the G1 domain
contains the HA-binding regions, which consist of two Link domains of ~93 amino acids with homology to the Link domains found in other hyalectins such as the hyaluronic acid receptor for endocytosis
(HARE), TSG-6, CD44, and lymphatic vascular endothelial hyaluronan receptor 1 (LYVE-1) (Harris &
Weigel in Vasta & Ahmed, Animal Lectins [2009], Chapter 12). Another ECM protein called “Link protein” (due to its function of “linking” aggrecan and HA) binds to both HA, with its own Link domain,
and the G1 domain of aggrecan via an Ig-fold [22]. This trimeric (HA-Link protein-aggrecan) complex
creates a stable and long-lasting three-dimensional structure that is strong, yet flexible enough to withstand the high-impact physical forces constantly experienced by our joints and tissues. Binding studies
using surface plasmon resonance show that a fragment of aggrecan comprising G1 and G2 binds HA
with a Kd of 226 nM, whereas the Link protein binds HA with a Kd of 89 nM, a higher affinity [23].
The G2 domain shares some structural features with G1, but lacks the ability to bind HA. It is
heavily substituted with KS chains and N-terminally adjacent to the CS attachment region. Both G1
and G2 domains inhibit aggrecan monomer secretion until the protein is fully modified and correctly
folded. On the other hand, the G3 domain is known to promote secretion of the monomer and progression of the protein along the secretory pathway after GAG addition [24]. The region between the
G1 and G2 domains, the interglobular domain (IGD region), is cleaved by proteolysis during normal
aggrecan turnover. Conditions in which there is an increased exposure to, or expression of, inflammatory cytokines (e.g., as found in arthritis) promote the degeneration of aggrecan and weakening of
the cartilage. The loss of the G2 through G3 portion of aggrecan changes the physicochemical attributes of the HA-aggrecan aggregate structure, which is difficult to repair, since the G1 domain fragment may remain bound to HA and thus prevent the binding of newly synthesized intact aggrecan
monomers with HA [25–27].
The G3 or C-terminal domain of aggrecan contains two EGF-like domains (EGF1 and EGF2), a
CRD, and a complement regulatory protein B component or short complement repeat (SCR). The
primary role of the G3 domain is to aid secretion of the aggrecan monomer from chondrocytes after
protein synthesis and GAG assembly in the ER/Golgi. The G3 domain is essentially a cap that prevents degradation, while the individual subdomains within G3 assist with processing, trafficking,
and secretion of the heavily glycosylated core protein [28, 29]. The G3 domain in articular cartilage is
primarily associated with newly synthesized or immature aggrecan, whereas most mature aggrecan
core proteins have lost their G3 domains in age-related processes [30].
Assembly of the aggrecan supramolecular structure is a highly ordered process that begins on
the chondrocyte surface. In humans, HA is made at the cell surface by any of the three membranebound HA synthase isozymes (HAS1, 2, or 3) [31–33]. As HA is extruded from the cell surface, newly
synthesized aggrecan and Link proteins may bind with the HA to form aggregates. The Link protein is required for proper alignment and ordering of the aggrecan along the HA [34]. The details for
how Link protein is secreted and helps assemble these structures are not known. Furthermore, since
cartilage is an acellular tissue, special processes are needed to facilitate the assembly of new ECM
components many cell diameters away from the site of synthesis. One facilitation mechanism is that
not all immature aggrecan monomers can bind HA, which is advantageous for development, since
these aggrecan monomers then have time to travel away from the cell (i.e., the site of synthesis) before they become anchored to a HA molecule. This delayed incorporation of aggrecan may be the result of structural changes in the G1 domain [35, 36], or the interaction of the G3 domain with other
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ECM structural proteins such as fibulin 1/2, tenacin-C and tenacin-R [37]. Unincorporated aggrecan
has a short half-life, 24 h or less, whereas aggrecan incorporated into HA aggregates has a half-life of
many years [38]. The immature unassociated aggrecan monomer needs to undergo several physical
changes, depending on the environment, or it will be degraded. Once aggrecan binds with HA and
Link protein, the molecule is very stable and can proceed to assemble into supramolecular aggregates with other aggrecan and ECM molecules such as biglycan, decorin, fibulin, and the collagens.
3 Versican
Human versican is a “versatile” molecule found in the ECM of connective tissues and the ECMs
of a wide variety of “soft” tissues, including brain, arterial and venous vasculature, epithelia, and
mesenchyme. The full-length core protein is the longest of the four lecticans, discussed in this chapter, and is encoded by a gene that extends over 100 kb and includes 15 exons. The core protein is organized in a fashion similar to the other lecticans (Figure 1) with a HA-binding globular G1 domain
at the N-terminus and two GAG attachment domains, termed GAG- and GAG-β, in the middle region encoded by 3 and 5.3 kb exons, respectively. The C-terminal portion of the protein contains two
EGF-like domains, a CRD and a complement regulatory region. Alternative splicing of versican results in three variants (termed V1, V2, and V3), as well as full-length (V0), that are encoded by 3, 9,
6.5, and 12 kb transcripts, respectively. The molecular masses for these variants (V0–V3) are 370, 262,
180, and 72 kDa. V1 does not include GAG-, V2 does not contain GAG-β, andV3 lacks both GAG attachment regions and is, therefore, technically not a proteoglycan [19].
Versican is the major proteoglycan in most arteries and veins, where it interacts with HA and
Link proteins to form stable high molecular mass aggregates that fill spaces not occupied by other
proteins such as collagen and elastin. The interaction of versican with other proteins and HA provide
the blood vessels with walls that are both firm and elastic, thus able to contract or dilate in response
to blood pressure, temperature changes, etc. In addition to normal turnover, inflammation and aging
promote the degradation of versican, a process in which the core protein is cleaved by members of
the ADAMS-TS metalloproteases family, in addition to matrilysin and plasmin. The loss of versican
in the blood vessel walls may contribute to a weakening of the overall structure, giving rise to aneurysms and pseudoaneurysms [39, 40].
Arterial smooth muscle cells (ASMC) are the primary source of versican in both arteries and blood
vessels and express the transcripts to produce V0, V1, and V3 [41, 42]. Platelet-derived growth factor,
through the MAP kinase pathway, stimulates an increase in versican core protein transcription and
CS chain elongation [43]. Conversely, IL-1β produced by inflammatory-stimulated macrophages decreases versican expression, suggesting that macrophage binding to vasculature lesions may contribute to the versican breakdown associated with this pathology [44]. Versican enriched with CS-6 and
CS-4 chains is involved in the advanced stages of atherosclerotic lesions. Versican is prominent near
the edges of necrotic cores and in close proximity to lipoproteins [45]. In vitro binding studies demonstrate that multiple low-density lipoprotein (LDL) particles can bind to single CS chains with an
affinity of 23 nM, and an increase in chain length directly correlates with increased binding of LDL
particles with the same affinity [18, 46]. Treatment of ASMCs with growth factors such as EGF and
TGF-β also causes elongation of CS chains on versican and may serve as a positive feedback stimulus
in the early stages of atherogenesis [47, 48].
The increased expression of versican V2, a product of oligodendrocytes, occurs in the periphery of
brain lesions. In vitro cultures of oligodendrocytes indicate that the expressed versican acts as a linker
between HA and tenascin-R, forming a rudimentary ECM. Axon regeneration failure is induced due
to this injury response, since versican mediates growth-cone collapse and growth inhibition through
its CS chains and core protein sequence [49]. Since all of the lecticans, including versican, present in
the brain are growth-inhibitory, several methods to eliminate versican have been devised in order to
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promote axon regeneration. These include the use of antiversican antibodies to eliminate versican expressing cells via complement-killing in the rat [50] and the infusion of antimitotic agents to prevent
oligodendrocyte recruitment to the lesion [51].
4 Neurocan
The rat brain proteoglycan, neurocan, was identified and characterized using monoclonal antibodies [52]. During embryonic development, neurocan is commonly found as a 250 kDa monomer,
and then later during maturation, it occurs as two protein isoforms of 130 and 150 kDa due to proteolysis at a MMP-2 cleavage site [53]. The N-terminal 130 kDa segment is the major HA-binding component and contains two CS chains, while the C-terminal 150 kDa segment binds with other ECM
proteins and calcium ions [54]. Expression of neurocan is confined to the CNS, although it is present in the developing sensory nerves of the optical and olfactory systems in lower animals [55, 56]. In
mature brain, the expression of neurocan is very low, but is markedly increased in areas undergoing
matrix remodeling. In fact, expression of neurocan may be required for remodeling of hippocampal
synaptic connections during learning and memory-induced changes in synaptic transmissions [57].
Neurocan interacts with other molecules via the core protein, its GAG chains, or both. Interacting partners of neurocan can be classified into three different groups. First, the matrix proteins tenascin-C and tenascin-R are important for ECM aggregation during brain development when neurocan
and heparin, which enhances the activity, are localized to perineuronal nets (PNNs) [58, 59]. Second, growth factors associated with mobility such as FGF-2 [60], HB-GAM, and amphoterin [61] interact with neurocan and also bind heparin. Binding with amphoterin and HB-GAM is CS-chain dependent in contrast to FGF-2, which binds to the core protein. These growth factors support neurite
outgrowth and extension in the developing brain, whereas neurocan serves as a modulator for these
growth factors. Third, neural cell adhesion molecules such as N-CAM, L1/Ng-CAM, and TAG-1/axonin-1 are involved with neurite outgrowth and navigation. Binding of these cell adhesion molecules
is CS-dependent, although there is weak binding to the C-terminal portion of the core protein.
Although neurocan interacts with a wide variety of adhesion, growth, and matrix molecules, the
neurocan knockout mouse does not exhibit any gross anatomical brain pathologies [62]. Despite the
involvement of neurocan in modeling of the CNS matrix, the proteoglycan is not required for the final outcome of how the brain structure develops. Thus far, the phenotypes of neurocan deficiency
have only been observed in mice and give no indication of the possible affects on higher-brain functions such as thought and reasoning. Interestingly, an L1/Ng-CAM deficiency causes mental retardation in humans, but causes no physical or mental manifestation in mice, proving that not all animal models reflect the human condition [63].
5 Brevican
Expression of brevican or brain-enriched hyaluronan-binding protein (BEHAB) is restricted to the
brain and is particularly enriched in neuroglial sheaths of velate protoplasmic astrocytes in the cerebellar granular layer [64] and in PNNs of large neurons [65]. In the rat, brevican is expressed at high
levels in the neuroaxis of the ventricular zones and may be important for the development of glial
cells. Brevican was first discovered in rats and cats as a partial protein with a molecular mass of ~38
kDa [66]. The full-length 160 kDa core protein is now known to be proteolytically cleaved, resulting
in two physiologically relevant fragments of 100 and 60 kDa [67].
The ECM of the brain contains cross-linking proteins called the tenascins, which serve not only as
part of the lattice that supports the neuronal network of the brain, but also as coregulators of morphogenesis and remodeling associated with injury, learning, and growth. Neurocan binds strongly
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with tenascin-C, and both proteins increase in expression during tissue regeneration [68]. On the
other hand, brevican binds with tenascin-R via its fibronectin III domain in a CS-independent manner [69]. Tenascin-R, HA, and the lecticans, especially brevican and neurocan, are basic components
of the PNNs first described by Camillo Golgi and Santiago Ramon y Cajal in the 1890s. Neurons and
glial cells secrete the materials that compose the PNN, which is a reticular net-like feature covering
these cells that forms the organized lattice material in the intercellular spaces [65]. The PNN, which is
structurally similar in some ways to the aggrecan-HA proteoglycan aggregates of cartilage, provides
a tougher shield to protect the enclosed neurons and glial cells from movement within an otherwise
vulnerable soft tissue matrix.
Brevican is a unique marker for glioma, a type of cancer that originates within the glial cells of
the brain and metastasizes very extensively within the cranial ECM, but does not extend outside
the CNS boundaries [70]. One of the main features of a high-grade glioma is the presence of an underglycosylated form of brevican (B/bΔg), which migrates at 150 kDa on sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Other forms of brevican are also present, such as
a differentially glycosylated form that migrates slightly larger than 160 kDa and the proteolytic byproducts of ADAMTS-4-induced cleavage of the native protein [71–73]. These features are not present in other neuropathologies such as Alzheimer’s disease, nonglial tumors, or Parkinson’s disease.
Like the other lecticans, brevican exerts its inhibitory control on neurite outgrowth and cell migration via it CS chains. Brevican (B/bΔg), a likely agent for glioma aggressiveness, may tip the balance
in the favor of growth and migration of neurons.
6 Conclusion and Future Directions
Once thought to be ECM components that only hold tissues and organs in place, the lecticans are
increasing recognized as dynamic molecules that influence cell behaviors through effector protein/
GAG interactions and signaling pathways. The underlying causes of many intrinsic human diseases,
such as Alzheimer’s disease and stenosis, can be traced to a “malfunction” of one or more lecticans.
The binding partners and matrix associations of this class of molecules are fairly well understood.
More exciting future directions will focus on gene regulation and the development of transgenic
mice with reporter genes inserted within the promoter regions of versican, brevican, and neurocan.
Since little is known about the cis or trans regulatory elements of how these genes are turned on or
off, the expression of reporter genes in conjunction with lectican expression will provide answers to
questions such as how protein expression corresponds with injury or disease and what regulates that
expression. Since the versican knockout is lethal in mice, reporter genes in this model and others will
aid our understanding of gene expression during development, disease, and injury and may ultimately provide targets for gene therapeutic interventions.
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